Professor Jonathan Kimmelman, Director of the Biomedical Ethics Unit, participated in a Globe and Mail panel on stem cells.
Category:
Published on: 9 Dec 2021
Professor Jonathan Kimmelman, Director of the Biomedical Ethics Unit, is among the experts quoted by The Globe and Mail.
Category:
Published on: 3 Dec 2021
Professor Jonathan Kimmelman, Director of the Biomedical Ethics Unit is among the experts quoted by STAT.
Category:
Published on: 21 Oct 2021
Professor Jonathan Kimmelman, Director of the Biomedical Ethics Unit is among the experts quoted by FiveThirtyEight.
Category:
Published on: 5 Aug 2021
U.S. government health officials approved the first new drug for Alzheimer's disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn't been shown to help slow the brain-destroying disease. The Food and Drug Administration (FDA) said it granted approval to the drug from Biogen based on results that seemed “reasonably likely” to benefit Alzheimer's patients. (CTV News)
Category:
Published on: 10 Jun 2021
Professor Jonathan Kimmelman, Director of the Biomedical Ethics Unit is among the experts quoted in this piece about the AstraZeneca vaccine.
"…“It’s one thing for a drug company or sponsor to bungle this on the first go but this is the second time this company has released information that was inaccurate and confusing, and it’s incredibly frustrating,” said Jonathan Kimmelman, a bioethicist at McGill University."
Category:
Published on: 25 Mar 2021
Experts working in the field of vaccine development tend to believe that an effective vaccine is not likely to be available for the general public before the fall of 2021. In a paper published recently in the Journal of General Internal Medicine, a McGill-led team published the results of a recent survey of 28 experts working in vaccinology.
Category:
Published on: 1 Oct 2020
Thousands of healthy volunteers, including hundreds of Canadians, have offered to try getting injected with a potential vaccine and then purposely becoming infected with COVID-19 to test if the vaccine works. Jonathan Kimmelman, a professor of biomedical ethics at McGill University, expressed concerns about the risks.
Category:
Published on: 19 May 2020
Jonathan Kimmelman, director of biomedical ethics at McGill University, agreed companies have some obligation to continue to provide care for patients who take part in studies to test experimental products. “Any time a patient participates in a trial, they’re volunteering their body to advance science,” he said from Montreal. “And if it’s a trial being run by a pharmaceutical company, they’re volunteering their bodies to advance the goals of the pharmaceutical company, whether that’s a big pharmaceutical company or a small one.
Category:
Published on: 27 Mar 2018
I talked this over with McGill University medical ethicist Jonathan Kimmelman, who specializes in the risks of medical experiments and has written a book about them centered on the Jesse Gelsinger case. Of course, he says, money isn’t the only thing that might prevent medical researchers from being perfectly objective -- there’s the desire to be heroes, to beat rivals, and to help patients. A bigger concern is the fact that whatever is driving scientists, they can have blind spots just like everyone else.
Category:
Published on: 23 Jan 2018
Category:
Published on: 31 Aug 2017
Cancer scientists overestimate the extent to which high-profile preclinical studies can be successfully replicated, new research from McGill University suggests.
Category:
Published on: 29 Jun 2017
Badly designed studies may lead to the efficacy of drugs being overestimated and money being wasted on trials that prove fruitless, according to a new study from McGill University in Canada.
Category:
Published on: 14 Oct 2015
